Artivion, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James Patrick Mackin
- Full Time Employees
- 1,800
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1655 Roberts Boulevard N.W. Kennesaw GA United States of America 30144
- IPO Date
- Feb 12, 1993
- CIK
- 0000784199
- Website
- artivion.com
- Similar Companies
- Business
- Artivion, Inc. Artivion, Inc. (AORT) is a medical device company that manufactures, processes, and distributes implantable human tissues and innovative medical devices focused on addressing cardiac and vascular surgeons' challenges in treating patients with aortic diseases; its core products and services span four primary families including aortic stent grafts such as the NEXUS®, NEXUS DUO™, NEXUS TRE™, E-vita® Open Neo, and Neo EDE™ hybrid arch devices, surgical sealants led by BioGlue® Surgical Adhesive, On-X® mechanical heart valves and related surgical products for aortic and mitral valve replacement, and preservation services for implantable cardiac and vascular human tissues encompassing CryoValve® SG pulmonary human heart valve, CryoValve® aortic allograft, CryoPatch® SG pulmonary patch, CryoGraft® descending thoracic aorta, CryoArtery® aortoiliac and femoral artery grafts, CryoVein® saphenous vein, femoral vein, and pediatric conduit allografts, as well as ancillary solutions like CarbonAid® CO2 diffuser and E-xtra Design Engineering custom stent grafts. Founded in 1984 and headquartered in Kennesaw, Georgia, the company operates globally with over 1,600 employees, manufacturing and sales representation across North America, EMEA, LATAM, and APAC, serving hospitals and surgeons through its two reportable segments of Medical Devices and Preservation Services. Recent developments include the U.S. FDA granting a Humanitarian Device Exemption in December 2024 for the AMDS Hybrid Prosthesis in acute DeBakey Type I aortic dissections with malperfusion, presentation of positive one-year data from the AMDS PERSEVERE trial at the 61st Society of Thoracic Surgeons Annual Meeting in January 2025 demonstrating reduced mortality and major adverse events, launch of the Artivex stent graft system in EMEA in 2024, a $350 million senior secured credit facility with Ares Management Credit funds closed in January 2024 comprising a $190 million term loan, $100 million delayed draw term loan, and $60 million revolver to refinance debt, completion of enrollment in the PERSEVERE trial in 2023, and a rebranding from CryoLife to Artivion in January 2022 to emphasize its aortic disease focus following strategic acquisitions like On-X Life Technologies in 2016, JOTEC AG in 2017, and Ascyrus Medical in 2020.
Company News
Artivion Q2 Earnings Call Highlights
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion Reports Second Quarter 2026 Financial Results
Artivion to Participate in Upcoming Investor Conferences
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Fifth Third Bancorp Buys 123,023 Shares of Artivion, Inc. $AORT
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion to Participate in the 2026 Truist Securities MedTech Conference
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Artivion Completes Acquisition of Endospan Ltd.
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion Q1 Earnings Call Highlights
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan